- Home
- OSRH vs SABS Comparison
OSRH vs SABS Comparison
Compare OSRH & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSRH
- SABS
- Stock Information
- Founded
- OSRH N/A
- SABS 2014
- Country
- OSRH United States
- SABS United States
- Employees
- OSRH N/A
- SABS N/A
- Industry
- OSRH
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- OSRH
- SABS Health Care
- Exchange
- OSRH Nasdaq
- SABS Nasdaq
- Market Cap
- OSRH 19.0M
- SABS 15.8M
- IPO Year
- OSRH N/A
- SABS N/A
- Fundamental
- Price
- OSRH $0.53
- SABS $2.22
- Analyst Decision
- OSRH
- SABS Strong Buy
- Analyst Count
- OSRH 0
- SABS 5
- Target Price
- OSRH N/A
- SABS $10.00
- AVG Volume (30 Days)
- OSRH 1.3M
- SABS 4.3M
- Earning Date
- OSRH 08-14-2025
- SABS 08-07-2025
- Dividend Yield
- OSRH N/A
- SABS N/A
- EPS Growth
- OSRH N/A
- SABS N/A
- EPS
- OSRH N/A
- SABS N/A
- Revenue
- OSRH N/A
- SABS $114,698.00
- Revenue This Year
- OSRH N/A
- SABS N/A
- Revenue Next Year
- OSRH N/A
- SABS N/A
- P/E Ratio
- OSRH N/A
- SABS N/A
- Revenue Growth
- OSRH N/A
- SABS N/A
- 52 Week Low
- OSRH $0.52
- SABS $1.00
- 52 Week High
- OSRH $13.40
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- OSRH N/A
- SABS 49.35
- Support Level
- OSRH N/A
- SABS $1.94
- Resistance Level
- OSRH N/A
- SABS $2.26
- Average True Range (ATR)
- OSRH 0.00
- SABS 0.21
- MACD
- OSRH 0.00
- SABS -0.03
- Stochastic Oscillator
- OSRH 0.00
- SABS 55.22
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.